VCNX Vaccinex Inc

5,604

$0.7099

$0.0191

(2.62%)

Today

Watchers	5,604
52-Wk Low	$0.5801
52-Wk High	$12.36

Market Cap	$7.75M
Volume (M)	45,292.00
52-Wk High	$12.36
52-Wk Low	$0.5801

Fundamentals

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleGlobe Newswire • 1 day ago

Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer's Disease on Schedule to Complete Treatment in June 2024...

Share to Feed

Vaccinex GAAP EPS of -$1.09, revenue of $0.02MSeekingAlpha.com: All News • 22 days ago

Vaccinex GAAP EPS of -$1.09, revenue of $0.02M...

Vaccinex reports Q3 EPS ($1.09) vs. ($1.67) last yearThe Fly • 23 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobe Newswire • 23 days ago

Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual MeetingGlobe Newswire • about 1 month ago

Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with...

Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Down 37.8% in OctoberZolmax • about 1 month ago

Vaccinex, Inc. (NASDAQ:VCNX Get Free Report) was the recipient of a large decrease in short interest in October. As of October 15th, there was short interest totalling 198,000 shares, a...

Vaccinex announces presentation of findings for pepinemabThe Fly • about 1 month ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesGlobe Newswire • about 1 month ago

Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient bloodROCHESTER, N.Y., Oct...

Vaccinex Announces Pricing of $9.6 Million Public OfferingGlobe Newswire • 2 months ago

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ( Vaccinex or the Company ), a clinical-stage biotechnology company pioneering a differentiated approach to...

Vaccinex to present update on PDAC/Pepinemab study, new ActivMAb applicationThe Fly • 2 months ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...